About Novatec G2

---

In 2022, I took a massive risk.  I left a great job, great boss, wonderful colleagues, my company of 17 years, and the pharmaceutical industry, where I'd spent my entire career, for an opportunity at a healthcare giant: leading a large research organization and a portfolio of projects developing healthcare-services, quality improvement initiatives, and AI/ML innovations.  Unfortunately, just a couple of years in, a series of reorganizations eliminated my position and most of my team.  I left feeling disoriented and wondering, where do I go from here?

Reflecting on the past 3 years I realize the gifts this experience has given me: new skills; new ideas that would have never crossed my mind had I stayed put in Pharma; a broad and deep network of talented people in AI/ML, new scientific disciplines including social, network, and actuarial, care delivery, informatics, and more.  I was exposed to vastly different company cultures, leadership styles, and workplace norms, which greatly help shape me as a leader.  Most of all, my creativity was reignited.

And now it's time for me to go back to what I know and love: innovating to make clinical development work better for everyone. And helping healthcare solve problems with solutions that they may have never heard of but are commonplace in clinical trials.  

I am an accomplished clinical and healthcare innovation executive, having delivered solutions in partnership with numerous technology and service entreprenuers and through industry collaborations, including TransCelerate. I've pioneered  the application of "usability research" to design and operations of clinical trials, to ensure they're doable for participants, investigators, and staff before finalizing things. I spearheaded and led Johnson & Johnson's program for decentralized clinical trials. For my work in innovation, I was named a PharmaVoice 100 honoree and winner of the 2017 Clinical & Research Excellence (CARE) award. 

Before this, I led global clinical trial teams in pharmaceutical and biotech companies, providing hands-on and end-to-end oversight of trials in all development phases and multiple therapy areas. I consistently achieved trial recruitment on time, within budget, and impeccable quality, contributing to the regulatory approval of several life-changing drugs and vaccines.

I hold a Master of Public Health in Epidemiology from Emory University, a Master of Business Administration in Pharmaceutical Management from Drexel University, and a Bachelor of Science in Molecular Biology and Biochemistry from the University of Idaho.